Nanoviricides (FRA:NV3P) Short Interest

View and export this data going back to . Start your Free Trial

What is Nanoviricides Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Nanoviricides's Short Interest

For the Biotechnology subindustry, Nanoviricides's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanoviricides's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoviricides's Short Interest distribution charts can be found below:

* The bar in red indicates where Nanoviricides's Short Interest falls into.

Nanoviricides Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (FRA:NV3P) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

NNVC:USA NV3P:Germany

Address

1 Controls Drive, Shelton, CT, USA, 06484

Website

http://www.nanoviricides.com

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Nanoviricides Headlines

No Headlines